Generic Name and Formulations:
Lubiprostone 8mcg, 24mcg; caps.
Company:
Sucampo and Takeda
Irritable bowel syndrome with constipation (IBS–C) in women.
Take with food and water. ≥18yrs: 8mcg twice daily. Severe hepatic impairment (Child-Pugh Class C): 8mcg once daily.
<18yrs: not recommended.
GI motility enhancer (chloride channel activator).
Known or suspected mechanical GI obstruction.
Confirm absence of GI obstruction before starting therapy. Severe diarrhea: not recommended. Renal or hepatic impairment. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers; monitor infants for diarrhea.
Nausea, headache, diarrhea (suspend therapy if occurs), abdominal pain, abdominal distension, flatulence, dyspnea, vomiting, syncope, asthenia, others.
Renal (primary), fecal.
8mcg—60; 24mcg—60, 100
Chronic idiopathic constipation.
Take with food and water. 24mcg twice daily. Moderate hepatic impairment (Child-Pugh Class B): 16mcg twice daily. Severe hepatic impairment (Child-Pugh Class C): 8mcg twice daily.
Not recommended.
GI motility enhancer (chloride channel activator).
Known or suspected mechanical GI obstruction.
Confirm absence of GI obstruction before starting therapy. Severe diarrhea: not recommended. Renal or hepatic impairment. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers; monitor infants for diarrhea.
Nausea, headache, diarrhea (suspend therapy if occurs), abdominal pain, abdominal distension, flatulence, dyspnea, vomiting, syncope, asthenia, others.
Renal (primary), fecal.
8mcg—60; 24mcg—60, 100